应交易所要求,美/港股行情延时15分钟展示,下载APP即可免费查看实时行情。
关闭
CYTK Cytokinetics
已收盘 11-06 16:00:00 EST
60.30
+1.11
+1.88%
盘后
60.28
-0.02
-0.03%
19:55 EST
最高
61.29
最低
58.05
成交量
220.47万
今开
58.85
昨收
59.19
日振幅
5.47%
总市值
72.36亿
流通市值
71.81亿
总股本
1.20亿
成交额
1.32亿
换手率
1.85%
流通股本
1.19亿
市净率
--
ROE
--
每股收益
0.00
52周最高
--
52周最低
--
市盈率
--
股息
--
股息收益率
--
ROA
--
分时
五日
日K
周K
月K
数据加载中...
北京优虎网络科技有限公司
资讯
新帖
简况
Cytokinetics宣布将于2025年在肥厚型心肌病医学协会科学会议和美国心脏协会科学会议上进行多场演讲
美股速递 · 10-31
Cytokinetics宣布将于2025年在肥厚型心肌病医学协会科学会议和美国心脏协会科学会议上进行多场演讲
Cytokinetics将发行可转换优先票据筹集最多5.5亿美元
环球市场播报 · 09-17
Cytokinetics将发行可转换优先票据筹集最多5.5亿美元
Cytokinetics宣布定价6.5亿美元扩大规模可转换优先票据发行;为2027年可转换票据部分进行再融资
美股速递 · 09-17
Cytokinetics宣布定价6.5亿美元扩大规模可转换优先票据发行;为2027年可转换票据部分进行再融资
Cytokinetics——若Aficamten获FDA批准,公司仍预期其将具备差异化标签和风险缓解特征——SEC文件显示
美股速递 · 09-17
Cytokinetics——若Aficamten获FDA批准,公司仍预期其将具备差异化标签和风险缓解特征——SEC文件显示
Cytokinetics盘后股价下跌4.2%,宣布拟发行5.5亿美元可转换优先债券
美股速递 · 09-17
Cytokinetics盘后股价下跌4.2%,宣布拟发行5.5亿美元可转换优先债券
百事涨5.8%激进投资机构Elliott Management已持有其40 亿美元股份。Cytokinetics涨27.
智通财经 · 09-02
百事涨5.8%激进投资机构Elliott Management已持有其40 亿美元股份。Cytokinetics涨27.
Cytokinetics公布Maple-HCM研究主要结果,在2025年欧洲心脏病学会大会发表并刊登于《新英格兰医学杂志》
美股速递 · 08-30
Cytokinetics公布Maple-HCM研究主要结果,在2025年欧洲心脏病学会大会发表并刊登于《新英格兰医学杂志》
Cytokinetics:接受阿菲卡坦治疗的患者中51%在NYHA功能分级上有一个或多个等级改善,而接受美托洛尔治疗的患者仅为26%
美股速递 · 08-30
Cytokinetics:接受阿菲卡坦治疗的患者中51%在NYHA功能分级上有一个或多个等级改善,而接受美托洛尔治疗的患者仅为26%
Cytokinetics:积极试验结果显示Aficamten优于标准治疗药物β受体阻滞剂美托洛尔
美股速递 · 08-30
Cytokinetics:积极试验结果显示Aficamten优于标准治疗药物β受体阻滞剂美托洛尔
Cytokinetics:与美托洛尔相比,Aficamten使NT-proBNP降低81%并显著改善左心房容积指数
美股速递 · 08-30
Cytokinetics:与美托洛尔相比,Aficamten使NT-proBNP降低81%并显著改善左心房容积指数
Cytokinetics宣布将在2025年欧洲心脏病学会大会上发表五项Aficamten相关研究报告
美股速递 · 08-25
Cytokinetics宣布将在2025年欧洲心脏病学会大会上发表五项Aficamten相关研究报告
Cytokinetics, Incorporated盘中异动 早盘股价大涨5.28%
市场透视 · 07-31
Cytokinetics, Incorporated盘中异动 早盘股价大涨5.28%
Cytokinetics, Incorporated盘中异动 股价大涨5.05%
市场透视 · 07-09
Cytokinetics, Incorporated盘中异动 股价大涨5.05%
小摩:维持Cytokinetics(CYTK.US)评级,由增持调整至增持评级, 目标价由71.00美元调整至53.00美元。
金融界 · 06-09
小摩:维持Cytokinetics(CYTK.US)评级,由增持调整至增持评级, 目标价由71.00美元调整至53.00美元。
瑞穗银行:维持Cytokinetics评级,由优于大市调整至优于大市评级, 目标价由103.00美元调整至84.00美元。
金融界 · 05-30
瑞穗银行:维持Cytokinetics评级,由优于大市调整至优于大市评级, 目标价由103.00美元调整至84.00美元。
Cytokinetics, Incorporated盘中异动 下午盘股价大涨5.04%
市场透视 · 05-21
Cytokinetics, Incorporated盘中异动 下午盘股价大涨5.04%
Cytokinetics, Incorporated盘中异动 股价大涨5.04%
市场透视 · 05-17
Cytokinetics, Incorporated盘中异动 股价大涨5.04%
异动解读 | Cytokinetics股价盘中大跌5.01%,心脏病药物研究达主要目标却未能提振股价
异动解读 · 05-16
异动解读 | Cytokinetics股价盘中大跌5.01%,心脏病药物研究达主要目标却未能提振股价
异动解读 | 心脏病药物试验成功,Cytokinetics盘前大涨5.01%
异动解读 · 05-16
异动解读 | 心脏病药物试验成功,Cytokinetics盘前大涨5.01%
异动解读 | Cytokinetics股价盘中大跌5.01%,心脏病药物研究达主要目标却未能提振股价
异动解读 · 05-13
异动解读 | Cytokinetics股价盘中大跌5.01%,心脏病药物研究达主要目标却未能提振股价
加载更多
公司概况
公司名称:
Cytokinetics
所属市场:
NASDAQ
上市日期:
--
主营业务:
Cytokinetics, Incorporated于1997年8月5日成立,符合特拉华州的法律规定。它是一家处于临床阶段的生物制药公司,主要致力于为重大疾病和糟糕的医疗条件提供潜在的治疗方法的这样一种调节肌肉功能的新型小分子治疗方法的发现和发展。它目前处于发展阶段,着重于科研,开发药品筛选技术和融资。
发行价格:
--
{"stockData":{"symbol":"CYTK","market":"US","secType":"STK","nameCN":"Cytokinetics","latestPrice":60.3,"timestamp":1762462800000,"preClose":59.19,"halted":0,"volume":2204671,"hourTrading":{"tag":"盘后","latestPrice":60.28,"preClose":60.3,"latestTime":"19:55 EST","volume":285037,"amount":17187691.1285,"timestamp":1762476939575},"delay":0,"floatShares":119088114,"shares":120000000,"eps":-5.118189,"marketStatus":"已收盘","change":1.11,"latestTime":"11-06 16:00:00 EST","open":58.85,"high":61.29,"low":58.05,"amount":132227630.093888,"amplitude":0.054739,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-5.118189,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1762506000000},"marketStatusCode":5,"adr":0,"adrRate":0,"listingDate":1083211200000,"exchange":"NASDAQ","adjPreClose":59.19,"preHourTrading":{"tag":"盘前","latestPrice":59.09,"preClose":59.19,"latestTime":"09:25 EST","volume":1153,"amount":68160.70188000001,"timestamp":1762439100011},"postHourTrading":{"tag":"盘后","latestPrice":60.28,"preClose":60.3,"latestTime":"19:55 EST","volume":285037,"amount":17187691.1285,"timestamp":1762476939575},"volumeRatio":1.309974,"impliedVol":0.4771,"impliedVolPercentile":0.02},"requestUrl":"/m/hq/s/CYTK","defaultTab":"news","newsList":[{"id":"1159228276","title":"Cytokinetics宣布将于2025年在肥厚型心肌病医学协会科学会议和美国心脏协会科学会议上进行多场演讲","url":"https://stock-news.laohu8.com/highlight/detail?id=1159228276","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1159228276?lang=zh_cn&edition=full","pubTime":"2025-10-31 19:31","pubTimestamp":1761910297,"startTime":"0","endTime":"0","summary":"Cytokinetics宣布将于2025年在肥厚型心肌病医学协会科学会议和美国心脏协会科学会议上进行多场演讲","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","CYTK","BK4505","BK4139","BK4585"],"gpt_icon":0},{"id":"2568496296","title":"Cytokinetics将发行可转换优先票据筹集最多5.5亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2568496296","media":"环球市场播报","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2568496296?lang=zh_cn&edition=full","pubTime":"2025-09-17 20:42","pubTimestamp":1758112920,"startTime":"0","endTime":"0","summary":"周三盘前,生物制药公司Cytokinetics(CYTK)上涨0.6%,此前该公司宣布,计划通过发行2031年到期的可转换优先票据筹集最多5.5亿美元资金。\n\n\n海量资讯、精准解读,尽在新浪财经APP\n\n责任编辑:张俊 SF065","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2025-09-17/doc-infqvhrz2546128.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["CYTK","BK4585","BK4139","BK4588","BK4505"],"gpt_icon":0},{"id":"1181470114","title":"Cytokinetics宣布定价6.5亿美元扩大规模可转换优先票据发行;为2027年可转换票据部分进行再融资","url":"https://stock-news.laohu8.com/highlight/detail?id=1181470114","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1181470114?lang=zh_cn&edition=full","pubTime":"2025-09-17 11:46","pubTimestamp":1758080777,"startTime":"0","endTime":"0","summary":"Cytokinetics宣布定价6.5亿美元扩大规模可转换优先票据发行;为2027年可转换票据部分进行再融资","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","BK4585","CYTK","BK4139","BK4505"],"gpt_icon":0},{"id":"1107967207","title":"Cytokinetics——若Aficamten获FDA批准,公司仍预期其将具备差异化标签和风险缓解特征——SEC文件显示","url":"https://stock-news.laohu8.com/highlight/detail?id=1107967207","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1107967207?lang=zh_cn&edition=full","pubTime":"2025-09-17 04:13","pubTimestamp":1758053597,"startTime":"0","endTime":"0","summary":"Cytokinetics——若Aficamten获FDA批准,公司仍预期其将具备差异化标签和风险缓解特征——SEC文件显示","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CYTK","BK4139","BK4588","BK4505","BK4585"],"gpt_icon":0},{"id":"1122526064","title":"Cytokinetics盘后股价下跌4.2%,宣布拟发行5.5亿美元可转换优先债券","url":"https://stock-news.laohu8.com/highlight/detail?id=1122526064","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1122526064?lang=zh_cn&edition=full","pubTime":"2025-09-17 04:10","pubTimestamp":1758053451,"startTime":"0","endTime":"0","summary":"Cytokinetics盘后股价下跌4.2%,该公司宣布拟通过私募方式发行价值5.5亿美元的可转换优先债券。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","CYTK","BK4585","BK4505","BK4588"],"gpt_icon":0},{"id":"2564388606","title":"百事涨5.8%激进投资机构Elliott Management已持有其40 亿美元股份。Cytokinetics涨27.","url":"https://stock-news.laohu8.com/highlight/detail?id=2564388606","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2564388606?lang=zh_cn&edition=full","pubTime":"2025-09-02 21:30","pubTimestamp":1756819857,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["LU0359201885.HKD","BEKE","LU1051768304.USD","LU0359201612.USD","CSTA.U","LU1188198961.HKD","LU1051769294.HKD","LU1831875114.USD","BK4079","LU1688375341.USD","BK4504","LU0244354667.USD","BK4505","LU1023057109.AUD","LU0651946864.USD","BK4509","LU0287142896.SGD","LU0326950275.SGD","BK4139","LU1515016050.SGD","BK4548","CYTK","LU0651947912.USD","BK4585","LU0359202008.SGD","LU0463099449.HKD","BK4588","LU0173614495.USD","BK4526"],"gpt_icon":0},{"id":"1141869495","title":"Cytokinetics公布Maple-HCM研究主要结果,在2025年欧洲心脏病学会大会发表并刊登于《新英格兰医学杂志》","url":"https://stock-news.laohu8.com/highlight/detail?id=1141869495","media":"美股速递","labels":["conferences"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1141869495?lang=zh_cn&edition=full","pubTime":"2025-08-30 15:20","pubTimestamp":1756538435,"startTime":"0","endTime":"0","summary":"Cytokinetics宣布了其Maple-HCM研究的主要结果,相关数据已在2025年欧洲心脏病学会大会上进行了展示,同时研究成果也已发表在权威医学期刊《新英格兰医学杂志》上。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","CYTK","BK4585","BK4139","BK4505"],"gpt_icon":0},{"id":"1100177896","title":"Cytokinetics:接受阿菲卡坦治疗的患者中51%在NYHA功能分级上有一个或多个等级改善,而接受美托洛尔治疗的患者仅为26%","url":"https://stock-news.laohu8.com/highlight/detail?id=1100177896","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1100177896?lang=zh_cn&edition=full","pubTime":"2025-08-30 15:20","pubTimestamp":1756538430,"startTime":"0","endTime":"0","summary":"Cytokinetics:接受阿菲卡坦治疗的患者中51%在NYHA功能分级上有一个或多个等级改善,而接受美托洛尔治疗的患者仅为26%","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CYTK","BK4139","BK4588","BK4585","BK4505"],"gpt_icon":0},{"id":"1116510698","title":"Cytokinetics:积极试验结果显示Aficamten优于标准治疗药物β受体阻滞剂美托洛尔","url":"https://stock-news.laohu8.com/highlight/detail?id=1116510698","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1116510698?lang=zh_cn&edition=full","pubTime":"2025-08-30 15:20","pubTimestamp":1756538428,"startTime":"0","endTime":"0","summary":"Cytokinetics:积极试验结果显示Aficamten优于标准治疗药物β受体阻滞剂美托洛尔","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CYTK","BK4505","BK4585","BK4588","BK4139"],"gpt_icon":0},{"id":"1167884525","title":"Cytokinetics:与美托洛尔相比,Aficamten使NT-proBNP降低81%并显著改善左心房容积指数","url":"https://stock-news.laohu8.com/highlight/detail?id=1167884525","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1167884525?lang=zh_cn&edition=full","pubTime":"2025-08-30 15:20","pubTimestamp":1756538421,"startTime":"0","endTime":"0","summary":"Cytokinetics公司宣布,与美托洛尔相比,其药物Aficamten能够使NT-proBNP水平降低81%,并在左心房容积指数方面实现显著改善。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","CYTK","BK4585","BK4139","BK4505"],"gpt_icon":0},{"id":"1107188140","title":"Cytokinetics宣布将在2025年欧洲心脏病学会大会上发表五项Aficamten相关研究报告","url":"https://stock-news.laohu8.com/highlight/detail?id=1107188140","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1107188140?lang=zh_cn&edition=full","pubTime":"2025-08-25 19:31","pubTimestamp":1756121493,"startTime":"0","endTime":"0","summary":"Cytokinetics宣布将在2025年欧洲心脏病学会大会上发表五项与Aficamten相关的研究报告。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CYTK","BK4139","BK4505","BK4588","BK4585"],"gpt_icon":0},{"id":"2555397038","title":"Cytokinetics, Incorporated盘中异动 早盘股价大涨5.28%","url":"https://stock-news.laohu8.com/highlight/detail?id=2555397038","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2555397038?lang=zh_cn&edition=full","pubTime":"2025-07-31 22:17","pubTimestamp":1753971466,"startTime":"0","endTime":"0","summary":"北京时间2025年07月31日22时17分,Cytokinetics, Incorporated股票出现异动,股价急速拉升5.28%。Cytokinetics, Incorporated股票所在的生物技术行业中,整体涨幅为2.74%。Cytokinetics, Incorporated公司简介:细胞动力科技有限公司是一家后期生物技术公司,开发肌肉生物学驱动的治疗以肌肉功能降低、肌肉无力和疲劳为特征的疾病。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250731221747a46dc641&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250731221747a46dc641&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4588","CYTK","BK4585","BK4139","BK4505"],"gpt_icon":0},{"id":"2550655742","title":"Cytokinetics, Incorporated盘中异动 股价大涨5.05%","url":"https://stock-news.laohu8.com/highlight/detail?id=2550655742","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2550655742?lang=zh_cn&edition=full","pubTime":"2025-07-09 22:24","pubTimestamp":1752071044,"startTime":"0","endTime":"0","summary":"北京时间2025年07月09日22时24分,Cytokinetics, Incorporated股票出现异动,股价大幅拉升5.05%。Cytokinetics, Incorporated股票所在的生物技术行业中,整体涨幅为1.29%。Cytokinetics, Incorporated公司简介:细胞动力科技有限公司是一家后期生物技术公司,开发肌肉生物学驱动的治疗以肌肉功能降低、肌肉无力和疲劳为特征的疾病。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250709222404a4408f66&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250709222404a4408f66&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4585","CYTK","BK4505","BK4139","BK4588"],"gpt_icon":0},{"id":"2542336147","title":"小摩:维持Cytokinetics(CYTK.US)评级,由增持调整至增持评级, 目标价由71.00美元调整至53.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2542336147","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2542336147?lang=zh_cn&edition=full","pubTime":"2025-06-09 23:54","pubTimestamp":1749484488,"startTime":"0","endTime":"0","summary":"小摩:维持Cytokinetics(CYTK.US)评级,由增持调整至增持评级, 目标价由71.00美元调整至53.00美元。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/06/09235450957649.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["CYTK"],"gpt_icon":0},{"id":"2539671602","title":"瑞穗银行:维持Cytokinetics评级,由优于大市调整至优于大市评级, 目标价由103.00美元调整至84.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2539671602","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2539671602?lang=zh_cn&edition=full","pubTime":"2025-05-30 00:31","pubTimestamp":1748536293,"startTime":"0","endTime":"0","summary":"瑞穗银行:维持Cytokinetics(CYTK.US)评级,由优于大市调整至优于大市评级, 目标价由103.00美元调整至84.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250530003414950721cb&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250530003414950721cb&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["CYTK"],"gpt_icon":0},{"id":"2537647114","title":"Cytokinetics, Incorporated盘中异动 下午盘股价大涨5.04%","url":"https://stock-news.laohu8.com/highlight/detail?id=2537647114","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2537647114?lang=zh_cn&edition=full","pubTime":"2025-05-21 02:04","pubTimestamp":1747764262,"startTime":"0","endTime":"0","summary":"北京时间2025年05月21日02时04分,Cytokinetics, Incorporated股票出现波动,股价快速拉升5.04%。Cytokinetics, Incorporated股票所在的生物技术行业中,整体涨幅为0.89%。Cytokinetics, Incorporated公司简介:细胞动力科技有限公司是一家后期生物技术公司,开发肌肉生物学驱动的治疗以肌肉功能降低、肌肉无力和疲劳为特征的疾病。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250521020422a6e659a1&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250521020422a6e659a1&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["CYTK","BK4139","BK4505","BK4588","BK4585"],"gpt_icon":0},{"id":"2536343799","title":"Cytokinetics, Incorporated盘中异动 股价大涨5.04%","url":"https://stock-news.laohu8.com/highlight/detail?id=2536343799","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2536343799?lang=zh_cn&edition=full","pubTime":"2025-05-17 00:46","pubTimestamp":1747414008,"startTime":"0","endTime":"0","summary":"北京时间2025年05月17日00时46分,Cytokinetics, Incorporated股票出现异动,股价快速上涨5.04%。Cytokinetics, Incorporated股票所在的生物技术行业中,整体涨幅为0.34%。其相关个股中,Affimed N.V.、Inozyme Pharma, Inc.、Nls Pharmaceutics Ltd C/Wts 02/02/2026涨幅较大,Affimed N.V.、Polyrizon Ltd.、Nucana Plc较为活跃,换手率分别为4879.95%、2933.78%、1438.71%,振幅较大的相关个股有Affimed N.V.、Onconetix, Inc.、Vor Biopharma Inc.,振幅分别为466.98%、66.89%、66.82%。Cytokinetics, Incorporated公司简介:细胞动力科技有限公司是一家后期生物技术公司,开发肌肉生物学驱动的治疗以肌肉功能降低、肌肉无力和疲劳为特征的疾病。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025051700464994f92dd3&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025051700464994f92dd3&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","CYTK","BK4588","BK4505","BK4585"],"gpt_icon":0},{"id":"1175650490","title":"异动解读 | Cytokinetics股价盘中大跌5.01%,心脏病药物研究达主要目标却未能提振股价","url":"https://stock-news.laohu8.com/highlight/detail?id=1175650490","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1175650490?lang=zh_cn&edition=full","pubTime":"2025-05-16 14:53","pubTimestamp":1747378439,"startTime":"0","endTime":"0","summary":"生物制药公司Cytokinetics周二盘中股价大跌5.01%,引发市场关注。这一跌势与公司刚刚公布的积极消息形成鲜明对比,该公司宣布其试验性心脏病药物在一项后期研究中已达到主要目标。尽管公司传出利好消息,但投资者似乎并未对此作出积极反应。作为一家专注于肌肉生物学的生物制药公司,Cytokinetics的这款心脏病药物的成功对公司未来发展至关重要。然而,从当前股价走势来看,市场似乎对公司前景持谨慎态度。","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["CYTK"],"gpt_icon":0},{"id":"1118875737","title":"异动解读 | 心脏病药物试验成功,Cytokinetics盘前大涨5.01%","url":"https://stock-news.laohu8.com/highlight/detail?id=1118875737","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1118875737?lang=zh_cn&edition=full","pubTime":"2025-05-16 14:53","pubTimestamp":1747378382,"startTime":"0","endTime":"0","summary":"生物制药公司Cytokinetics(CYTK)周二盘前股价大涨5.01%,引起投资者广泛关注。\n\n根据路透社报道,Cytokinetics公司于5月13日宣布,其试验性心脏病药物在一项后期研究中达到了主要目标。这一积极的研究结果是推动公司股价大幅上涨的主要原因。\n\n后期临床试验的成功对于制药公司来说至关重要,因为它为药物获得监管机构批准和最终商业化铺平了道路。虽然公司尚未公布详细的试验数据,但这一结果无疑增强了投资者对Cytokinetics未来发展前景的信心。如果该心脏病药物最终获得批准并成功上市,将可能为公司带来可观的收入增长,从而进一步提升其在生物制药行业的地位。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["CYTK"],"gpt_icon":0},{"id":"1131370405","title":"异动解读 | Cytokinetics股价盘中大跌5.01%,心脏病药物研究达主要目标却未能提振股价","url":"https://stock-news.laohu8.com/highlight/detail?id=1131370405","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1131370405?lang=zh_cn&edition=full","pubTime":"2025-05-13 22:36","pubTimestamp":1747147003,"startTime":"0","endTime":"0","summary":"生物制药公司Cytokinetics周二盘中股价大跌5.01%,引发市场关注。这一跌势与公司刚刚公布的积极消息形成鲜明对比,该公司宣布其试验性心脏病药物在一项后期研究中已达到主要目标。尽管公司传出利好消息,但投资者似乎并未对此作出积极反应。作为一家专注于肌肉生物学的生物制药公司,Cytokinetics的这款心脏病药物的成功对公司未来发展至关重要。然而,从当前股价走势来看,市场似乎对公司前景持谨慎态度。","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["CYTK"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.cytokinetics.com","stockEarnings":[{"period":"1week","weight":-0.0452},{"period":"1month","weight":-0.0239},{"period":"3month","weight":0.6791},{"period":"6month","weight":0.8675},{"period":"1year","weight":0.127},{"period":"ytd","weight":0.2583}],"compareEarnings":[{"period":"1week","weight":-0.0143},{"period":"1month","weight":0.0089},{"period":"3month","weight":0.0717},{"period":"6month","weight":0.2007},{"period":"1year","weight":0.1749},{"period":"ytd","weight":0.1561}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Cytokinetics, Incorporated于1997年8月5日成立,符合特拉华州的法律规定。它是一家处于临床阶段的生物制药公司,主要致力于为重大疾病和糟糕的医疗条件提供潜在的治疗方法的这样一种调节肌肉功能的新型小分子治疗方法的发现和发展。它目前处于发展阶段,着重于科研,开发药品筛选技术和融资。","yearOnYearQuotes":[{"month":1,"riseRate":0.47619,"avgChangeRate":0.002524},{"month":2,"riseRate":0.47619,"avgChangeRate":-0.024236},{"month":3,"riseRate":0.47619,"avgChangeRate":-0.003116},{"month":4,"riseRate":0.619048,"avgChangeRate":0.016608},{"month":5,"riseRate":0.590909,"avgChangeRate":0.01979},{"month":6,"riseRate":0.409091,"avgChangeRate":-0.000087},{"month":7,"riseRate":0.681818,"avgChangeRate":0.060358},{"month":8,"riseRate":0.636364,"avgChangeRate":0.040484},{"month":9,"riseRate":0.409091,"avgChangeRate":0.034179},{"month":10,"riseRate":0.318182,"avgChangeRate":-0.070805},{"month":11,"riseRate":0.454545,"avgChangeRate":0.01492},{"month":12,"riseRate":0.47619,"avgChangeRate":0.104126}],"exchange":"NASDAQ","name":"Cytokinetics","nameEN":"Cytokinetics"},"APP":{"userAgent":"CCBot/2.0 (https://commoncrawl.org/faq/)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.35.5","shortVersion":"4.35.5","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Cytokinetics(CYTK)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Cytokinetics(CYTK)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Cytokinetics,CYTK,Cytokinetics股票,Cytokinetics股票老虎,Cytokinetics股票老虎国际,Cytokinetics行情,Cytokinetics股票行情,Cytokinetics股价,Cytokinetics股市,Cytokinetics股票价格,Cytokinetics股票交易,Cytokinetics股票购买,Cytokinetics股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Cytokinetics(CYTK)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Cytokinetics(CYTK)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}